Visiopharm, Boston Cell Standards to develop IHC technology

October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in Archives of Pathology & Laboratory Medicine (Magnani B, et al. Published online July 26, 2023. doi:10.5858/arpa.2023-0048-ED).

“The combination of our two companies’ products represents a traditional instrument analyzer-reagent system. Qualitopix is the instrument and the calibrators/controls are the reagents,” Dr. Michael Grunkin, CEO of Visiopharm, said in a joint press release.
The companies are planning to complete the initial integration and start clinical testing this year.

Boston Cell Standards, 617-636-8042
Visiopharm, 877-843-5268